Abstract
This study elucidates key factors influencing the risk of perinephric hematoma post-SWL, highlighting the importance of procedural adjustments such as the stepwise ramping protocol to reduce complications. These insights call for targeted patient and treatment strategy optimization to enhance SWL safety and efficacy.
Introduction
Extracorporeal Shockwave Lithotripsy (SWL) has remained a cornerstone in the non-invasive management of renal calculi since its introduction in the 1980s. Despite its widespread use, the incidence of perinephric hematoma—a potentially serious complication—remains a subject of debate. Literature reports vary significantly, with incidence rates ranging from less than 1% to as high as 30%. This discrepancy is largely attributed to variations in study design and the sensitivity of post-procedural imaging. Many previous studies relied on symptomatic presentation or ultrasound, which may overlook smaller, subclinical bleeds. This study aims to provide a definitive analysis of risk factors using a large prospective cohort and high-sensitivity cross-sectional imaging.
Methods
A post-hoc analysis was conducted on 573 adult patients enrolled in two randomized controlled trials (RCTs), CUHK_CCT00462 and CUHK_CCRB00510, between 2016 and 2022. Inclusion criteria focused on patients with solitary renal stones measuring 5 to 15 mm. All procedures were performed using a Storz Modulith SLX-F2 electromagnetic lithotripter.
To ensure accurate detection of both symptomatic and "radiographic" hematomas, a standardized imaging protocol was implemented: every patient underwent either a non-contrast CT scan or an MRI exactly two days post-SWL. Multivariate logistic regression was employed to identify independent predictors of hematoma formation among patient, stone, and treatment-related variables.
Results
The study identified a radiographic hematoma incidence rate of 30.9%, significantly higher than many previous reports. Notably, only 1.7% of patients experienced clinical symptoms, such as severe pain, highlighting the prevalence of "invisible" complications. Multivariate analysis identified several statistically significant factors that independently predicted hematoma formation.
Key findings from the multivariate model include:
- Total Energy Delivered: Higher energy delivery correlated with increased risk (p = 0.003).
- Mean Stone Density: Harder stones (measured in Hounsfield Units) significantly increased risk (OR = 2.603, p = 0.01).
- Lower Pole Location: Stones located in the lower pole were associated with a higher risk of hematoma (OR = 1.545, p = 0.029).
- Stepwise Ramping (Protective): Implementing a ramping protocol reduced the risk of hematoma by nearly half (OR = 0.572, p = 0.042).
Discussion
The high incidence of radiographic hematoma underscores the importance of procedural optimization. The protective effect of the stepwise ramping protocol—starting at a lower voltage (e.g., 10 kV) and gradually increasing to the target (14 kV)—is a critical finding. This approach likely acts as a "pre-treatment" that induces local vasoconstriction, making small blood vessels less likely to rupture during high-energy delivery.
Stone density serves as a significant risk proxy, likely because harder stones require more total energy to fragment or reflect shockwaves differently into the renal tissue. Similarly, the increased risk associated with lower pole stones may stem from the anatomical challenges of fragment clearance, which might lead clinicians to use higher energy levels. Interestingly, factors often cited in other studies—such as age, hypertension, and the use of antiplatelet medication (which was paused 7 days prior)—did not show a significant correlation in this specific cohort.
Conclusion
Standardized post-procedural imaging reveals that perinephric hematomas are far more common than previously recognized, even when asymptomatic. Clinicians should consider stone density and location when assessing risk and prioritize the use of stepwise ramping protocols to enhance the safety profile of SWL. Future research is needed to validate these findings across different populations and lithotripter technologies.
Summary updated